Nightingale Health Oyj

Nightingale Health Oyj maintains a strong liquidity position with EUR 41.29 million in cash and equivalents, representing 55.4% of total assets, and a current ratio of 8.8, well above the industry median of 1.8. The company's debt-to-equity ratio of 0.05 is significantly lower than the industry median of 0.4, indicating a conservative capital structure. The company's profitability metrics are negative, with a return on equity of -27.9% and return on assets of -24.8%, both far below the industry median of 12.5% and 8.3%, respectively. Operating and net losses of EUR 19.42 million and EUR 18.46 million, respectively, reflect ongoing investment in R&D and market expansion. Geographically, Nightingale operates in seven countries, with Finland as the parent jurisdiction and subsidiaries in the UK, Japan, Sweden, Germany, Singapore, Estonia, and the US. Revenue concentration data is not disclosed, but the global footprint suggests diversification. No single customer or segment accounts for more than 10% of revenue based on available disclosures. The company's growth trajectory is uncertain, with no revenue growth data provided in the latest financials. Analysts have assigned a mean price target of EUR 1.70, unchanged from the current share price, and a mean recommendation of 2.0 (Hold). No forward-looking revenue guidance is available in the input data. Risk factors include a negative operating cash flow of EUR -10.11 million and free cash flow of EUR -14.32 million, which could pressure liquidity if capital expenditures increase. However, the company has no immediate dilution or liquidity flags, and shares outstanding remain unchanged at 40.54 million. Recent events include no disclosed filings or transcripts in the input data. Analysts have issued one "Buy" recommendation and no "Strong Buy" or "Hold" ratings, suggesting limited near-term upside potential.